logo
Plus   Neg
Share
Email

Kite, HiFiBiO Join To Develop Antibodies Against Acute Myeloid Leukemia

Kite, a Gilead Company (GILD), and HiFiBiO Therapeutics have entered into a two-year research collaboration and license agreement in acute myeloid leukemia. HiFiBiO
will use its proprietary technology platforms to identify acute myeloid leukemia targets and anti-AML specific antibodies for Kite's use in cell therapies.

HiFiBiO will receive an upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to opt in on any targets discovered through the collaboration, for which HiFiBiO will receive an additional payment and will be eligible for additional milestone payments, as well as royalty payments.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. tech giant Google is laying the groundwork for a fiber-optic network that will connect the first time through Saudi Arabia and Israel, opening a new global internet traffic corridor, the Wall Street Journal reported, citing people familiar with the plans. The link would be established as part of an optical-fiber cable line connecting Europe with India. U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients.
Follow RTT